Quick Verdict
Zepbound (tirzepatide) produces more weight loss than Wegovy (semaglutide) at maximum doses, 20.9% vs 14.9%. Wegovy has a longer safety record and proven cardiovascular benefits. Zepbound is also about $290/month cheaper at brand pricing.
For pure weight loss, Zepbound has the edge. For heart protection, Wegovy is the proven option.
| Feature | Zepbound | Wegovy |
|---|---|---|
| Active Ingredient | Tirzepatide | Semaglutide |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Drug Class | Dual GIP/GLP-1 receptor agonist | GLP-1 receptor agonist |
| FDA Approved (Weight Loss) | November 2023 | June 2021 |
| Average Weight Loss (Max Dose) | 20.9% (SURMOUNT-1[1]) | 14.9% (STEP-1[2]) |
| Monthly Cost (Brand) | ~$1,060 | ~$1,350 |
| Monthly Cost (Compounded) | $149 to $399 | $199 to $399 |
| Dose Steps | 6 (2.5 to 15mg) | 5 (0.25 to 2.4mg) |
| Injection Frequency | Once weekly | Once weekly |
| CV Risk Reduction | Under investigation | 20%[4] MACE reduction (SELECT) |
How Much Weight Can You Lose on Zepbound vs Wegovy?
Zepbound delivers more weight loss at every comparable dose level. In the SURMOUNT-1 trial, patients on the highest Zepbound dose (15mg) lost an average of 20.9% of their body weight over 72 weeks. The STEP-1 trial showed Wegovy patients lost 14.9% over 68 weeks. For more details, see our guide on cheapest compounded tirzepatide.
For a 250-pound patient, that difference is roughly 15 additional pounds.
At the lowest Zepbound dose (5mg), weight loss was 15.0%, which matches Wegovy's maximum-dose result. This means even patients who can't tolerate higher Zepbound doses still get comparable results to full-dose Wegovy.
These are cross-trial comparisons, not a direct head-to-head at weight-loss doses. Patient populations and protocols differed slightly. But the SURPASS-2 trial[3] did compare tirzepatide directly against semaglutide (at lower diabetes doses) and found tirzepatide produced roughly double the weight loss at every dose level.
What Side Effects Should You Expect From Each?
Both medications share very similar side effect profiles because they work through overlapping biological pathways. Nausea is the most common complaint for both, affecting 20 to 44% of Wegovy patients and 24 to 33% of Zepbound patients in clinical trials. Most GI side effects are worst during the first few weeks of a new dose and improve with time. For more details, see our guide on cheapest compounded semaglutide. For a complete cost breakdown, see our best tirzepatide compounding pharmacies.
View data table
| Category | Overall Value Score | Detail |
|---|---|---|
| FormBlends | 92 | From $299/mo, physician-led |
| Hims/Hers | 78 | Consumer brand, varies |
| Ro | 75 | Telehealth platform |
| Calibrate | 70 | Metabolic health focus |
Check out our Zepbound before and after results for detailed data.
Vomiting is somewhat less common with Zepbound (5 to 12%) compared to Wegovy (5 to 24%). Constipation and diarrhea rates are comparable. About 4 to 7% of patients on either medication discontinue due to side effects.
Zepbound has one practical advantage in managing side effects: six dose steps compared to five for Wegovy. That extra granularity allows physicians to make smaller dose increases, which can reduce the severity of GI symptoms during titration.
How Does the Cost of Zepbound Compare to Wegovy?
At brand pricing, Zepbound is the cheaper option. Zepbound lists at about $1,060 per month while Wegovy runs about $1,350 per month. That $290 monthly difference adds up to about $3,480 per year. For more details, see our guide on Zepbound before and after results.
Not sure which GLP-1 is right for you?
Take a 2-minute assessment and get a personalized recommendation after licensed provider review.
Take the Assessment →Neither is affordable for most patients paying cash without insurance.
Insurance coverage is spotty for both. Wegovy has been available longer (June 2021 vs November 2023) and generally has broader formulary placement. Some plans cover Wegovy but not Zepbound, and vice versa.
Prior authorization requirements are common for both.
Compounded alternatives offer the most affordable path. Compounded tirzepatide (Zepbound's active ingredient) starts around $149 per month. Compounded semaglutide (Wegovy's active ingredient) starts around $199 per month.
FormBlends provides both through physician-supervised programs with licensed 503B pharmacy partners.
Does Wegovy Have Heart Benefits That Zepbound Does Not?
Yes, and this is Wegovy's most significant advantage. The SELECT trial[4] proved that semaglutide 2.4mg reduced major adverse cardiovascular events by 20% in patients with obesity and established heart disease. This was a key finding because no weight loss medication had previously demonstrated this kind of cardiovascular protection. For more details, see our guide on best GLP-1 without insurance.
Zepbound doesn't have equivalent data yet. The SURPASS-CVOT trial studying tirzepatide's cardiovascular outcomes is underway but results aren't expected until 2027. Early metabolic markers look promising, but hard endpoint data doesn't exist.
For patients with existing heart disease, a history of stroke, or high cardiovascular risk, this difference matters. Wegovy offers a layer of proven protection that Zepbound simply can't claim yet.
Which Is Better for Someone Just Starting GLP-1 Treatment?
For first-time GLP-1 patients focused on weight loss, either medication is a reasonable starting point. Zepbound's stronger weight loss data makes it appealing for patients who want maximum results. Wegovy's longer track record and cardiovascular data make it a conservative, well-supported choice. For more details, see our guide on Zepbound side effects.
Budget often becomes the deciding factor. If neither is covered by insurance, compounded versions of both active ingredients are available at a fraction of brand pricing. Many patients start with whichever compounded option their provider recommends, then adjust based on their individual response.
Your medical history should guide the conversation. Patients with cardiovascular risk factors may benefit from starting with Wegovy. Patients with type 2 diabetes may prefer Zepbound given tirzepatide's superior A1C data.
Patients without either complication can focus on whichever offers the best combination of cost and accessibility.
Can You Switch From Wegovy to Zepbound or Vice Versa?
Switching is straightforward and commonly done. When moving from Wegovy to Zepbound, most providers start at 2.5mg tirzepatide regardless of the previous Wegovy dose. When switching from Zepbound to Wegovy, providers typically start at a lower semaglutide dose and titrate up.
There's usually no washout period needed between the two.
Common reasons for switching include weight loss plateaus, side effect management, changes in insurance coverage, or simply wanting to try the other option. Some patients cycle between the two over time as their needs and circumstances evolve.
FormBlends supports both medications and can manage the transition smoothly with appropriate dose adjustments and monitoring during the switch period.
What About the Future of Both Medications?
Both Zepbound and Wegovy will face competition from next-generation drugs entering the market. Retatrutide (a triple-receptor agonist) showed up to 24% weight loss in Phase 2 trials. CagriSema combines semaglutide with an amylin analogue and delivered 22.7% weight loss.
Oral versions of both semaglutide and tirzepatide are in development.
For the foreseeable future, Zepbound and Wegovy remain the gold standard. They're FDA-approved, widely prescribed, and available in both brand and compounded forms. The decision between them comes down to personal health priorities, cost, and how your body responds.
Our clinical team at FormBlends stays current with all developments in this space. As new options become available, we help patients evaluate whether switching or adding to their current regimen makes sense.
Frequently Asked Questions
FormBlends
FormBlends is a U.S. telehealth platform that prescribes compounded semaglutide and tirzepatide. Patients complete an online intake, a licensed provider reviews eligibility, and medication ships from a 503A compounding pharmacy. Monthly pricing starts at $199. Start your intake.
Is Zepbound better than Wegovy for weight loss?
Clinical data favors Zepbound. SURMOUNT-1 showed Zepbound produced 20.9% weight loss at its highest dose vs 14.9% for Wegovy in STEP-1. Individual results vary based on dose, adherence, diet, and exercise habits.
How much do Zepbound and Wegovy cost without insurance?
Wegovy lists at about $1,350/month. Zepbound lists at about $1,060/month. Compounded alternatives start around $149 to $399/month through licensed pharmacies.
Do Zepbound and Wegovy have the same side effects?
Very similar. Both cause nausea, diarrhea, vomiting, and constipation. Rates are comparable across clinical trials and most symptoms fade within 4 to 8 weeks at a stable dose.
Can my doctor switch me from Wegovy to Zepbound?
Yes. Switching is common and safe. Your provider will start Zepbound at 2.5mg regardless of your Wegovy dose and titrate upward based on your tolerance and response.
Does insurance cover Zepbound or Wegovy?
Coverage varies widely. Wegovy has slightly broader coverage due to longer market presence. Many plans still exclude weight loss medications.
Check with your specific insurer for formulary details.
Which has a longer safety track record?
Wegovy. Its active ingredient (semaglutide) has been available since 2017. Zepbound's active ingredient (tirzepatide) has been available since 2022.
Semaglutide also has a completed cardiovascular outcomes trial.
Medical References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. [PubMed | DOI]
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →